113 related articles for article (PubMed ID: 38616512)
1. YTHDF2 promotes gastric cancer progression and enhances chemoradiotherapy resistance.
Yang J; Chen Y; He Y; Da M
Drug Dev Res; 2024 Apr; 85(2):e22179. PubMed ID: 38616512
[TBL] [Abstract][Full Text] [Related]
2. Wilms tumor 1 associated protein promotes epithelial mesenchymal transition of gastric cancer cells by accelerating TGF-β and enhances chemoradiotherapy resistance.
Liu Y; Da M
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3977-3988. PubMed ID: 36030434
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer.
Yang H; Hu Y; Weng M; Liu X; Wan P; Hu Y; Ma M; Zhang Y; Xia H; Lv K
J Adv Res; 2022 Mar; 37():91-106. PubMed ID: 35499052
[TBL] [Abstract][Full Text] [Related]
4. YTHDF2 Inhibits Gastric Cancer Cell Growth by Regulating FOXC2 Signaling Pathway.
Shen X; Zhao K; Xu L; Cheng G; Zhu J; Gan L; Wu Y; Zhuang Z
Front Genet; 2020; 11():592042. PubMed ID: 33505426
[TBL] [Abstract][Full Text] [Related]
5. YTHDF2 exerts tumor-suppressor roles in gastric cancer via up-regulating PPP2CA independently of m
Zhou Y; Fan K; Dou N; Li L; Wang J; Chen J; Li Y; Gao Y
Biol Proced Online; 2023 Mar; 25(1):6. PubMed ID: 36870954
[TBL] [Abstract][Full Text] [Related]
6. Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis.
Deng P; Sun M; Zhao WY; Hou B; Li K; Zhang T; Gu F
World J Gastroenterol; 2021 Feb; 27(6):487-500. PubMed ID: 33642823
[TBL] [Abstract][Full Text] [Related]
7. [Knockdown of YTH N
Zhang J; Pi J; Liu Y; Yu J; Feng T
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Dec; 33(12):1628-1634. PubMed ID: 29382422
[TBL] [Abstract][Full Text] [Related]
8. LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m
Fang Y; Wu X; Gu Y; Shi R; Yu T; Pan Y; Zhang J; Jing X; Ma P; Shu Y
Clin Transl Med; 2023 Mar; 13(3):e1205. PubMed ID: 36864711
[TBL] [Abstract][Full Text] [Related]
9. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy.
Chen JF; Wu P; Xia R; Yang J; Huo XY; Gu DY; Tang CJ; De W; Yang F
Mol Cancer; 2018 Jan; 17(1):6. PubMed ID: 29329543
[TBL] [Abstract][Full Text] [Related]
10. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
[TBL] [Abstract][Full Text] [Related]
11. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
[TBL] [Abstract][Full Text] [Related]
12. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21
Liu R; Miao J; Jia Y; Kong G; Hong F; Li F; Zhai M; Zhang R; Liu J; Xu X; Wang T; Liu H; Hu J; Yang Y; He A
Oncogene; 2023 May; 42(20):1607-1619. PubMed ID: 37012388
[TBL] [Abstract][Full Text] [Related]
14. LncRNA LINC00470 promotes the degradation of PTEN mRNA to facilitate malignant behavior in gastric cancer cells.
Yan J; Huang X; Zhang X; Chen Z; Ye C; Xiang W; Huang Z
Biochem Biophys Res Commun; 2020 Jan; 521(4):887-893. PubMed ID: 31711642
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer.
He C; Wang L; Zhang J; Xu H
Mol Cancer; 2017 Feb; 16(1):35. PubMed ID: 28173803
[TBL] [Abstract][Full Text] [Related]
16. Increase in Cisplatin Resistance by MeCP2 in Human Gastric Cancer through the Activation of the AKT Pathway by Facilitating PDK-1 Transcription.
Guo B; Cai S; Li W; Guo C; Liu Y; Ma X; Ma H; Zhao L
Curr Cancer Drug Targets; 2022; 22(5):414-425. PubMed ID: 35209822
[TBL] [Abstract][Full Text] [Related]
17. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.
Mei J; Liu G; Li R; Xiao P; Yang D; Bai H; Hao Y
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34821362
[TBL] [Abstract][Full Text] [Related]
18. circ-LDLRAD3 Knockdown Reduces Cisplatin Chemoresistance and Inhibits the Development of Gastric Cancer with Cisplatin Resistance through miR-588 Enrichment-Mediated SOX5 Inhibition.
Liang Q; Chu F; Zhang L; Jiang Y; Li L; Wu H
Gut Liver; 2023 May; 17(3):389-403. PubMed ID: 35975639
[TBL] [Abstract][Full Text] [Related]
19. [Knockdown of YTH N
Li Z; Luo Q; Wang H; Liu Y; Feng X; Li Z; Yi P
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Mar; 36(3):255-263. PubMed ID: 32389174
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA UFC1 promotes gastric cancer progression by regulating miR-498/Lin28b.
Zhang X; Liang W; Liu J; Zang X; Gu J; Pan L; Shi H; Fu M; Huang Z; Zhang Y; Qian H; Jiang P; Xu W
J Exp Clin Cancer Res; 2018 Jul; 37(1):134. PubMed ID: 29970131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
